Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Recurrence 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Hematologic Diseases 1Disease Progression 1Disease 1Blood Protein Disorders 1

Interventions

Lenalidomide 11Dexamethasone 11fludarabine 9Cyclophosphamide 7Bortezomib 6fludarabine phosphate 5Melphalan 5pomalidomide 4isatuximab 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Busulfan 3dacetuzumab 2Whole-Body Irradiation 2Thiotepa 2Stem Cell Transplantation 2Leukapheresis 2KW-2478 2Granulocyte Colony-Stimulating Factor 2Cyclosporine 2Calcium Dobesilate 2tanespimycin 1spartalizumab 1sargramostim 1ricolinostat 1pirtobrutinib 1pembrolizumab 1nirogacestat 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × ricolinostat × Plasma cell × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡